Literature DB >> 25113522

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

E Peñas-Lledó1, S Guillaume2, M E G Naranjo1, A Delgado1, I Jaussent3, H Blasco-Fontecilla4, P Courtet2, A LLerena5.   

Abstract

This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combination increases the likelihood of suicidal intent severity in a large study cohort. Survivors of a suicide attempt (n=587; 86.8% women) were genotyped for CYP2C19 (*2, *17) and CYP2D6 (*3, *4, *4xN, *5, *6, *10, wtxN) genetic variation and evaluated with the Beck Suicide Intent Scale (SIS). Patients with a high CYP2D6-CYP2C19 metabolic capacity showed an increased risk for a severe suicide attempt (P<0.01) as measured by the SIS-objective circumstance subscale (odds ratio (OR)=1.37; 95% confidence interval (CI)=1.05-1.78; P=0.02) after adjusting for confounders (gender, age, level of studies, marital status, mental disorders, tobacco use, family history of suicide, personal history of attempts and violence of the attempt). Importantly, the risk was greater in those without a family history of suicide (OR=1.82; CI=1.19-2.77; P=0.002). Further research is warranted to evaluate whether the observed relationship is mediated by the role of CYP2D6 and CYP2C19 involvement in the endogenous physiology or drug metabolism or both.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113522     DOI: 10.1038/tpj.2014.42

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  35 in total

1.  Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.

Authors:  A de Vos; J van der Weide; H M Loovers
Journal:  Pharmacogenomics J       Date:  2010-06-08       Impact factor: 3.550

Review 2.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

3.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

4.  The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.

Authors:  P W Schenk; M van Vliet; R A A Mathot; T van Gelder; A G Vulto; M A C van Fessem; S Verploegh-Van Rij; J Lindemans; J A Bruijn; R H N van Schaik
Journal:  Pharmacogenomics J       Date:  2009-11-03       Impact factor: 3.550

5.  CYP2D6 in the brain: impact on suicidality.

Authors:  J C Stingl; R Viviani
Journal:  Clin Pharmacol Ther       Date:  2011-01-19       Impact factor: 6.875

6.  High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

Authors:  E M Peñas-Lledó; P Dorado; Z Agüera; M Gratacós; X Estivill; F Fernández-Aranda; A Llerena
Journal:  Mol Psychiatry       Date:  2011-02-15       Impact factor: 15.992

7.  Association between CYP2C19 polymorphism and depressive symptoms.

Authors:  Sarah C Sim; Linn Nordin; Therese M-L Andersson; Susanne Virding; Marita Olsson; Nancy L Pedersen; Magnus Ingelman-Sundberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-09       Impact factor: 3.568

8.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

9.  CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Authors:  Thomas Rau; Gerlinde Wohlleben; Henrike Wuttke; Norbert Thuerauf; Jens Lunkenheimer; Mario Lanczik; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

10.  CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.

Authors:  Marianne Gex-Fabry; Chin B Eap; Beatrice Oneda; Nicola Gervasoni; Jean-Michel Aubry; Guido Bondolfi; Gilles Bertschy
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

View more
  10 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

Review 3.  Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk.

Authors:  Atmaram Yarlagadda; Kevin P Rosenblatt; Anita H Clayton
Journal:  Innov Clin Neurosci       Date:  2017-06-01

4.  Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.

Authors:  Ivan Skadrić; Oliver Stojković
Journal:  Int J Legal Med       Date:  2019-12-20       Impact factor: 2.686

5.  A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.

Authors:  Eva M Peñas-Lledó; Sebastien Guillaume; Fernando de Andrés; Ana Cortés-Martínez; Jonathan Dubois; Jean Pierre Kahn; Marion Leboyer; Emilie Olié; Adrián LLerena; Philippe Courtet
Journal:  Transl Psychiatry       Date:  2022-10-18       Impact factor: 7.989

6.  High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Authors:  G Moya; P Dorado; V Ferreiro; M E G Naranjo; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-04-12       Impact factor: 3.550

7.  Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6.

Authors:  Paul Y Takahashi; Euijung Ryu; Jyotishman Pathak; Gregory D Jenkins; Anthony Batzler; Matthew A Hathcock; John Logan Black; Janet E Olson; James R Cerhan; Suzette J Bielinski
Journal:  Pharmgenomics Pers Med       Date:  2017-02-14

8.  A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants.

Authors:  Sofia H Kanders; Claudia Pisanu; Marcus Bandstein; Jörgen Jonsson; Enrique Castelao; Giorgio Pistis; Mehdi Gholam-Rezaee; Chin B Eap; Martin Preisig; Helgi B Schiöth; Jessica Mwinyi
Journal:  Drug Dev Res       Date:  2019-10-16       Impact factor: 4.360

Review 9.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

10.  Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression.

Authors:  R C Culverhouse; N L Saccone; A C Horton; Y Ma; K J Anstey; T Banaschewski; M Burmeister; S Cohen-Woods; B Etain; H L Fisher; N Goldman; S Guillaume; J Horwood; G Juhasz; K J Lester; L Mandelli; C M Middeldorp; E Olié; S Villafuerte; T M Air; R Araya; L Bowes; R Burns; E M Byrne; C Coffey; W L Coventry; K A B Gawronski; D Glei; A Hatzimanolis; J-J Hottenga; I Jaussent; C Jawahar; C Jennen-Steinmetz; J R Kramer; M Lajnef; K Little; H M Zu Schwabedissen; M Nauck; E Nederhof; P Petschner; W J Peyrot; C Schwahn; G Sinnamon; D Stacey; Y Tian; C Toben; S Van der Auwera; N Wainwright; J-C Wang; G Willemsen; I M Anderson; V Arolt; C Åslund; G Bagdy; B T Baune; F Bellivier; D I Boomsma; P Courtet; U Dannlowski; E J C de Geus; J F W Deakin; S Easteal; T Eley; D M Fergusson; A M Goate; X Gonda; H J Grabe; C Holzman; E O Johnson; M Kennedy; M Laucht; N G Martin; M R Munafò; K W Nilsson; A J Oldehinkel; C A Olsson; J Ormel; C Otte; G C Patton; B W J H Penninx; K Ritchie; M Sarchiapone; J M Scheid; A Serretti; J H Smit; N C Stefanis; P G Surtees; H Völzke; M Weinstein; M Whooley; J I Nurnberger; N Breslau; L J Bierut
Journal:  Mol Psychiatry       Date:  2017-04-04       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.